人福醫藥(600079.SH)擬3.62億元向重藥集團轉讓四川人福70%股權
格隆匯8月5日丨人福醫藥(600079.SH)公佈,公司與重慶醫藥(集團)股份有限公司(以下簡稱“重藥集團”)簽署《四川人福醫藥有限公司股權轉讓合同》,擬以3.62億元將持有的四川人福醫藥有限公司(以下簡稱“四川人福”)70%股權轉讓給重藥集團。本次交易完成後,四川人福不再納入公司合併報表範圍。
本次出售四川人福70%股權,公司將在交易確認當期產生約2600萬元的非經常性損失,同時公司將收到3.62億元股權轉讓款、收回四川人福及其子公司借款約3億元並減少有息債務約10億元,有利於公司進一步優化資產負債結構,集中資源發展具有競爭優勢的細分領域,符合公司發展戰略和長遠利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.